FDA Approves Innoviva's Bacterial Pneumonia Treatment
23 Maio 2023 - 8:10PM
Dow Jones News
By Sabela Ojea
The Food and Drug Administration said Tuesday that it approved
Innoviva's Xacduro pneumonia treatment, which fights the
Acinetobacter bacteria.
The federal regulator said Xacduro, which treats
ventilator-associated bacterial pneumonia and hospital-acquired
bacterial pneumonia, is hard to treat and poses a great threat to
human health.
The FDA granted approval of Xacduro, administered by intravenous
infusion, to Entasis Therapeutics, acquired by the pharma company
Innoviva last year.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
May 23, 2023 18:55 ET (22:55 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Innoviva (NASDAQ:INVA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Innoviva (NASDAQ:INVA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
